ONCOassist

ONCOassist A revolutionary app designed by oncology professionals for oncology professionals. The go-to app for all oncology professionals.

It gives them comfort where they can access relevant, up to date tools and content at their fingertips. It is the only mobile-first platform that saves time and improves the quality of patient care for frustrated and under pressure oncology HCPs. With the advent of genomic sequencing, combined with an aging population, and new therapies. The decision-making process for oncology HCP's is becoming i

ncreasingly complex. Unfortunately, they have no easy access to the tools and information they need to make an informed decision quickly. This means they use multiple different software and tools to aid their decisions, many of which are not safe and validated. This wastes time & reduces the quality of patient care. We focus on making ONCOassist easily accessible to all oncology HCP’s by being available across multiple devices(iOS, Android, and Desktop) and ensuring safety through CE and FDA compliance. Such is the need for ONCOassist our community of users are actively engaging with us to help define our future tools based on their burning needs. ONCOassist is improving the delivery of cancer care globally and helping us to reach our goal of leveling the standard of care worldwide.

24/04/2026

🧮Calculate Risk of Bone Marrow Involvement For patients with Hodgkin Lymphoma on ONCOassist

Predicting bone marrow involvement in patients with Hodgkin's Lymphoma.

Download the ONCOassist app:
📥 iOS & Android: https://sn85wy.short.gy/qxrruq
📥Webapp: https://bit.ly/ONCOassistOnWeb

🚨 Latest   3 Update!🔷 Building on the KEYNOTE-048 trial, this real-world retrospective study compared Cisplatin and Carb...
24/04/2026

🚨 Latest 3 Update!

🔷 Building on the KEYNOTE-048 trial, this real-world retrospective study compared Cisplatin and Carboplatin in combination with Pembrolizumab and 5-FU in patients with recurrent or metastatic HNSCC. In 76 patients, Carboplatin demonstrated comparable efficacy to Cisplatin, with no significant differences in PFS (7.1 vs 4.1 months), OS (20.7 vs 14.8 months), or ORR (~34% in both arms), but with significantly lower toxicity.

🔷 These results may help optimize Pembrolizumab-based combination strategies in the real-world management of advanced HNSCC.

🔗 Read more: https://bit.ly/ONCOnews-24-Apr-01

🚨 Latest   3 Update!🔷 Perioperative pembrolizumab has shown event-free survival benefit in resectable head and neck squa...
23/04/2026

🚨 Latest 3 Update!

🔷 Perioperative pembrolizumab has shown event-free survival benefit in resectable head and neck squamous cell carcinoma in the Phase 3 KEYNOTE-689 trial, supporting its consideration as a treatment option in selected patients.

🔷 However, emerging analyses suggest that clinical benefit may be more pronounced in patients with higher PD-L1 expression (CPS ≥10), with limited response in lower CPS groups and potential concerns around toxicity and surgical outcomes, highlighting the need for careful patient selection

🔗 Read more: https://bit.ly/ONCOnews-Apr-23-01

23/04/2026

👉Access the complete quiz here: https://bit.ly/LOCC_ONCO_IQ_FB

📝This week’s ONCO-IQ challenge focuses on Localised Cervical Cancer. Comment the right answer below.

Explore localised cervical cancer and other oncology quizzes across multiple indications, now live on ONCOassist®.

🚨 Latest   Update!🔷 Ojemda® (Tovorafenib) has received EU conditional approval as a monotherapy for pediatric low‑grade ...
22/04/2026

🚨 Latest Update!

🔷 Ojemda® (Tovorafenib) has received EU conditional approval as a monotherapy for pediatric low‑grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation in patients 6 months of age and older who have progressed after one or more prior systemic therapies, marking a significant step forward in targeted treatment for this rare population.

🔷 In the Phase II FIREFLY‑1 trial, Tovorafenib demonstrated high response rates (ORR 71% per RANO‑HGG; 53% per RAPNO‑LGG), with durable responses (median duration of response 18.0 months per RAPNO‑LGG) and a manageable safety profile, supporting its clinical benefit in this setting.

🔗 Read more: https://bit.ly/ONCOnews-22-Apr-02

🚨 Latest   Update!🔷 Merck and Eisai have provided an update on the Phase 3 LITESPARK-012 trial evaluating Pembrolizumab ...
22/04/2026

🚨 Latest Update!

🔷 Merck and Eisai have provided an update on the Phase 3 LITESPARK-012 trial evaluating Pembrolizumab (KEYTRUDA®) + Lenvatinib (LENVIMA®) + Belzutifan (WELIREG®), and Pembrolizumab + Quavonlimab (MK-1308A) + Lenvatinib, versus Pembrolizumab + Lenvatinib in first-line advanced renal cell carcinoma.

🔷 At interim analysis, neither experimental combination met the dual primary endpoints of progression-free survival (PFS) and overall survival (OS), reinforcing Pembrolizumab plus Lenvatinib as the current standard of care in this setting.

🔗 Read more: https://bit.ly/ONCOnews-22-Apr-01

🎥 Oncology Bytes – IUCS 2025Dr Jack Hay, urology resident with the Manchester Andrology Research Collaborative, shares f...
22/04/2026

🎥 Oncology Bytes – IUCS 2025

Dr Jack Hay, urology resident with the Manchester Andrology Research Collaborative, shares findings on patient satisfaction after pe**le prosthesis insertion in men previously treated with radical pelvic uro-oncological therapy.

Watch here: https://youtu.be/mix6hE0IEM4

📊 Key findings:
No patients reported postoperative decision regret.
60% were very happy with their implant, with the remainder at least happy.
80% would definitely undergo the procedure again.
Cosmetic appearance remained an area of concern, with over 50% unsure or unhappy about pe**le cosmesis.
The presentation also reported encouraging postoperative sexual function and high overall satisfaction.

This abstract highlights pe**le prosthesis implantation as a promising option for carefully selected patients undergoing radical pelvic uro-oncological therapy, while underscoring the need for clear preoperative expectation-setting, particularly around cosmetic outcomes.

📄 Read the full abstract: https://urologycancersummit.org/iuc24422-79/
🗓️ Register for IUCS 2026: https://webplatform.planning.it/IUCS26/register

🌐 Learn more at: https://oncoassist.com/

**leProsthesis

Dr Jack Hay on Pe**le Prosthesis Outcomes After Radical Pelvic Uro-oncological Therapy | IUCS 2025

🚨 Latest   Update!🔷 Blenrep (Belantamab mafodotin) has been approved in China for the treatment of patients with relapse...
21/04/2026

🚨 Latest Update!

🔷 Blenrep (Belantamab mafodotin) has been approved in China for the treatment of patients with relapsed/refractory multiple myeloma who have received two or more prior lines of therapy. This approval expands access to a novel BCMA-targeted therapy for patients with limited treatment options.

🔷 In the Phase 3 DREAMM-7 trial, the combination reduced the risk of death by 42% and nearly tripled progression-free survival versus a daratumumab-based regimen, supporting its role as an effective and accessible outpatient treatment strategy.

🔗 Read more: https://bit.ly/ONCOnews-21-Apr-01

21/04/2026

👉️ Take the Localised Cervical Cancer ONCO-IQ now – https://bit.ly/LOCC_ONCO_IQ_FB

This peer-reviewed ONCO-IQ quiz is designed for oncology professionals; a fast, high-yield knowledge check you can complete in minutes.

✅️ Apply screening principles and know when to safely stop cervical cancer screening
✅️ Identify appropriate fertility-sparing surgical options in early-stage disease
✅️ Integrate evidence-based chemoradiation and immunotherapy strategies in locally advanced settings

🚨 Latest   Update!🔷 The Phase III AUGMENT trial 5-year follow-up demonstrates that Lenalidomide plus Rituximab provides ...
17/04/2026

🚨 Latest Update!

🔷 The Phase III AUGMENT trial 5-year follow-up demonstrates that Lenalidomide plus Rituximab provides sustained clinical benefit in patients with relapsed/refractory indolent non-Hodgkin lymphoma, with improved progression-free survival (HR 0.50) and overall survival (HR 0.59) at a median follow-up of ~66 months.

🔷 Subgroup analyses show consistent benefit across patient populations, including those aged ≥70 years, reinforcing the robustness of this combination and its role as a standard-of-care option in indolent NHL management.

🔗 Read more: https://bit.ly/ONCOnews-17-Apr-01

🚨 Latest   Update!🔷 Opna Bio has announced that OPN-6602, a dual EP300/CBP inhibitor, has received FDA Fast Track design...
16/04/2026

🚨 Latest Update!

🔷 Opna Bio has announced that OPN-6602, a dual EP300/CBP inhibitor, has received FDA Fast Track designation for relapsed/refractory multiple myeloma after at least four prior lines of therapy, highlighting its potential in a high unmet-need setting. The agent is currently being evaluated in a Phase 1 trial assessing safety and preliminary clinical activity.

🔷 Fast Track designation supports accelerated development and closer regulatory collaboration, underscoring growing momentum behind novel targeted approaches aimed at improving outcomes in heavily pretreated multiple myeloma.

🔗 Read more: https://bit.ly/ONCOnews-16-Apr-02

Address

3rd Floor, 41/42, High Street
Killarney
V93T8K7

Alerts

Be the first to know and let us send you an email when ONCOassist posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ONCOassist:

Share